|
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical research trials and Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors  Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
For Condition: Pancreatic Islet Cell Tumor,Neuroendocrine Tumor,Carcinoid Tumor
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The primary objective of the study is to determine the efficacy and safety of SU-011,248 as a treatment for patients with advanced unresectable neuroendocrine tumor.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Eligible patient must be at least 18 years of age with a diagnosis of carcinoid or pancreatic islet cell tumor. The disease must not be amenable to surgery, radiation, or combined modality therapy with curative intent. Any side effects from prior therapy must have subsided. Blood and urine tests must show adequate bone marrow, liver, and kidney function. Exclusion Criteria: The presence of any of the following will exclude a patient from study participation: diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, known brain or leptomeningeal disease, cardiovascular diseases or conditions, known HIV or AIDS-related illness, pregancy or breastfeeding. Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Total Enrollment:
Location and Contact Information:
Research Center *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting
Research Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting
Research Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02215
United States
Recruiting
Research Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting
Research Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting
Research Center *Recruiting*
Pinckneyville, Illinois, 62274
United States
Recruiting
Research Center *Recruiting*
San Francisco, California, 94143
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35233
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35233
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Research Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting
Additional Information:
Study ID Numbers: RTKC-0511-015;
Study Start Date: March 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056693
Other Pancreatic Islet Cell Tumor Studies:
1. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
Related Studies:
Other Pancreatic Islet Cell Tumor Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
|
|
|
|
|
|
|
|
